Zhen Zhang, PhD
Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, New Jersey
Original Research
Safety and Efficacy of Maintenance Treatment with Aripiprazole Once-Monthly in Black/African American Adults With Bipolar I Disorder
March 9, 2026
The safety and efficacy of AOM 400 were comparable between Black/African American and non-Black/African American patients with bipolar I disorder
Original Research
Safety and Efficacy of Aripiprazole 2-Month Ready-to-Use 960 mg
September 4, 2023
A new formulation of injectable aripiprazole for administration every 2 months showed similar rates of treatment-emergent adverse events to aripiprazole once-monthly 400 mg. Patients in both groups remained clinically...
